Vaibhav Agrawal MD MBA, MJ, MSHA
Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
1500 E. Duarte RoadDuarte, CA 91010
Overview of Dr. Agrawal
Dr. Vaibhav Agrawal, based in Duarte, CA, specializes in Hematology with subspecialties in Hematologic Oncology and Myeloproliferative Disorder Hematology-Oncology. He completed his Hematology Fellowship in 2021 at Stanford Health Care and holds an MD from Chicago Medical School. His employment history includes Research Associate at Helford Clinical Research Hospital and Assistant Clinical Professor at City of Hope, along with fellowships at Stanford University School of Medicine and Indiana University Health University Hospital. His experience covers immunotherapy, hematologic oncology, hematopoietic stem cell transplantation, bone marrow transplantation, and acute myeloid leukemia. Dr. Agrawal has several publications on topics relating to his field.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2021
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2017 - 2020
Geisinger Health SystemResidency, Internal Medicine/Pediatrics, 2013 - 2017
Loyola University Chicago School of LawM.J., Health Care Law, 2011 - 2015
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2013, MD- Loyola University ChicagoM.B.A., Healthcare Management, 2009 - 2011
- Rosalind Franklin University College of Health ProfessionsM.S., Health Care Administration, 2008 - 2011
Certifications & Licensure
CA State Medical License 2020 - 2026
IL State Medical License 2024 - 2026
IN State Medical License 2018 - 2021
PA State Medical License 2013 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Start of enrollment: 2024 Jul 12
Roles: Contact, Principal Investigator
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Start of enrollment: 2020 May 04
- A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients Start of enrollment: 2021 Jan 04
Publications & Presentations
PubMed
- Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T-cell precursor acute lymphoblastic leukaemia.Vaibhav Agrawal, Shukaib Arslan, Hoda Pourhassan, Paul Koller, Ibrahim Aldoss
British Journal of Haematology. 2025-04-09 - 1 citationsDelaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impact...Jose Tinajero, Sharon Xu, Dat Ngo, Shanpeng Li, Joycelynne Palmer
British Journal of Haematology. 2025-03-01 - Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect.Paul B Koller, Tamer Othman, Dongyun Yang, Sally Mokhtari, Yazeed Samara
Bone Marrow Transplantation. 2025-02-27
Committees
- Chair, House Staff Quality Council 2014 - 2017
Professional Memberships
- Member
- Member
- Member
- Member
- Member
- Member
Other Languages
- Hindi
External Links
- LinkedInhttp://www.linkedin.com/in/vaibhav-agrawal1
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
